We are a China-based neuro-interventional medical device pioneer with the aim of redefining the therapeutic and preventive paradigm of stroke. Leveraging our integrated capabilities in R&D, manufacturing and commercialization, we strive to reduce the mortality rate and improve prognosis of stroke in China and worldwide through the commercialization of our innovative product candidates.
We have a broad portfolio of 23 commercialized products and product candidates covering the entirety of the massive, fast-growing and highly under-penetrated neurointerventional market. Our portfolio extends from the treatment and prevention of ischemic stroke, including acute ischemic stroke and intracranial stenosis, to the treatment of hemorrhagic stroke. As of the Latest Practicable Date, we had obtained NMPA approvals for four ischemic stroke treatment devices forming a complete product suite for stent retrieving thrombectomy procedures. Additionally, we expect to commercialize nine currently late-stage product candidates in 2021 and 10 currently earlier-stage product candidates between 2022 and 2025, including the global-first sirolimus intracranial drug-eluting balloon catheter for intracranial stenosis treatment, thereby further expanding and diversifying our product offerings for the unmet and differentiated needs of stroke patients
Our innovative and comprehensive product portfolio, with one global-first and a number of domestic-first neuro-interventional devices, places us at the forefront of such revolution.
Company’s Keywords:
<2
<
<2016
Your request has been submitted successfully.
Own or work here?